Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Date
2018
Author
Spencer, Mike
Dimopoulos, Meletios A.
Robinson, Don
Potamianou, Anna
van de Velde, Helgi
Sargin, Deniz
Terpos, Evangelos
Katodritou, Eirini
de la Rubia, Javier
Hungria, Vania
Hulin, Cyrille
Roussou, Maria
Delforge, Michel
Bries, Greet
Stoppa, Anne-Marie
Aagesen, Jesper
Belch, Andrew
Ahlberg, Lucia
Diels, Joris
Olie, Robert A.
Metadata
Show full item record
Abstract
Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE (R) OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice.
URI
http://hdl.handle.net/20.500.12627/146016
https://doi.org/10.1111/ejh.13147
Collections